ArticleDermatology and therapy2022

Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.

Luigi Gargiulo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.